MARKET

ABBV

ABBV

AbbVie
NYSE

Real-time Quotes | Nasdaq Last Sale

102.18
+1.34
+1.33%
Pre Market: 103.23 +1.05 +1.03% 07:13 11/24 EST
OPEN
101.94
PREV CLOSE
100.84
HIGH
102.76
LOW
101.07
VOLUME
115
TURNOVER
--
52 WEEK HIGH
102.76
52 WEEK LOW
62.55
MARKET CAP
180.40B
P/E (TTM)
22.34
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
A top Democrat on the House antitrust panel sets sights on Big Pharma after wrapping up tech probe
Rep. Joe Neguse, D-Colo., wants the committee to examine the FTC's common approach to approving pharmaceutical mergers.
CNBC.com · 15m ago
3 Dividend Stocks Gurus Like
Wells Faro, Pfizer and AbbVie all enjoy the confidence of several gurus
GuruFocus.com · 20h ago
Did AbbVie Inc. (NYSE:ABBV) Insiders Buy Up More Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Simply Wall St. · 23h ago
AbbVie Announces Expiration and Final Results of Registered Exchange Offers
AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the expiration and final results of its offers to exchange (the "Registered Exchange Offers") any and all of its outstanding (i) $30,000,000,000 aggregate principal amount of senior unsecured notes previously issued on November 21, 2019 (the "2019 USD Notes"), (ii) $13,251,781,000 aggregate principal amount of senior unsecured notes previously issued on May 14, 2020 (the "2020 USD Notes" and, together with the 2019 USD Notes, the "USD Notes") and (iii) €2,517,066,000 aggregate principal amount of senior unsecured notes previously issued on May 14, 2020 (the "Euro Notes" and, together with the USD Notes, the "Original Notes"), each issued pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), for an equal principal amount of new notes in a transaction registered under the Securities Act (the "Registered Notes").
PR Newswire · 5d ago
AbbVie gains after BMO Capital points to positive pipeline
BMO Capital Markets starts off coverage on initiated AbbVie (ABBV) with an Outperform rating on what it calls a positive risk/reward profile.The firm is also positive on AbbVie's pipeline of
Seekingalpha · 5d ago
Here are Wednesday's biggest analyst calls of the day: Boeing, Tesla, Honeywell & more
Here are the biggest calls on Wall Street on Wednesday.
CNBC.com · 5d ago
Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and selling.
Benzinga · 6d ago
Looking Into AbbVie's Return On Capital Employed
Looking at Q3, AbbVie (NYSE: ABBV) earned $3.25 billion, a 332.85% increase from the preceding quarter. AbbVie also posted a total of $12.90 billion in sales, a 23.76% increase since Q2. AbbVie earned $752.00 million, and sales totaled $10.43 billion in Q2.What Is ROCE? Changes in earnings and sales indicate shifts in AbbVie's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, AbbVie posted an ROCE of 0.21%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on ABBVReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.For AbbVie, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.Q3 Earnings Recap AbbVie reported Q3 earnings per share at $2.83/share, which beat analyst predictions of $2.76/share.See more from Benzinga * Click here for options trades from Benzinga * What Does AbbVie's Debt Look Like? * Benzinga's Top Upgrades, Downgrades For November 10, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABBV. Analyze the recent business situations of AbbVie through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABBV stock price target is 111.33 with a high estimate of 127.00 and a low estimate of 97.00.
EPS
Institutional Holdings
Institutions: 3.04K
Institutional Holdings: 1.28B
% Owned: 72.31%
Shares Outstanding: 1.77B
TypeInstitutionsShares
Increased
1.02K
36.70M
New
217
18.84M
Decreased
885
72.88M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.87%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Chief Executive Officer/Director
Richard Gonzalez
President/Vice Chairman - Management
Michael Severino
Vice Chairman - Management
Carlos Alban
Vice Chairman - Management
Laura Schumacher
Chief Financial Officer/Senior Vice President
Robert Michael
Chief Human Resource Officer/Executive Vice President
Timothy Richmond
Executive Vice President - Finance
William Chase
Executive Vice President
Henry Gosebruch
Executive Vice President
Azita Saleki-Gerhardt
Senior Vice President
Nicholas Donoghoe
Senior Vice President
Jeffrey Stewart
Vice President/Controller
Brian Durkin
Lead Director/Independent Director
Glenn Tilton
Independent Director
Robert Alpern
Independent Director
Roxanne Austin
Independent Director
William Burnside
Independent Director
Thomas Freyman
Independent Director
Brett Hart
Independent Director
Edward Liddy
Independent Director
Melody Meyer
Independent Director
Edward Rapp
Independent Director
Rebecca Roberts
Independent Director
Frederick Waddell
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
10/30/2020
Dividend USD 1.3
01/14/2021
09/11/2020
Dividend USD 1.18
10/14/2020
06/17/2020
Dividend USD 1.18
07/14/2020
02/20/2020
Dividend USD 1.18
04/14/2020
11/01/2019
Dividend USD 1.18
01/14/2020
09/06/2019
Dividend USD 1.07
10/11/2019
06/20/2019
Dividend USD 1.07
07/12/2019
02/21/2019
Dividend USD 1.07
04/12/2019
11/02/2018
Dividend USD 1.07
01/14/2019
09/07/2018
Dividend USD 0.96
10/12/2018
06/14/2018
Dividend USD 0.96
07/12/2018
02/15/2018
Dividend USD 0.96
04/12/2018
10/26/2017
Dividend USD 0.71
01/11/2018
09/08/2017
Dividend USD 0.64
10/12/2017
06/23/2017
Dividend USD 0.64
07/12/2017
02/17/2017
Dividend USD 0.64
04/11/2017
10/31/2016
Dividend USD 0.64
01/11/2017
09/09/2016
Dividend USD 0.57
10/12/2016
06/16/2016
Dividend USD 0.57
07/13/2016
02/18/2016
Dividend USD 0.57
04/13/2016
10/30/2015
Dividend USD 0.57
01/13/2016
09/11/2015
Dividend USD 0.51
10/13/2015
06/19/2015
Dividend USD 0.51
07/13/2015
02/19/2015
Dividend USD 0.51
04/13/2015
10/21/2014
Dividend USD 0.49
01/13/2015
09/19/2014
Dividend USD 0.42
10/10/2014
06/19/2014
Dividend USD 0.42
07/11/2014
02/20/2014
Dividend USD 0.42
04/11/2014
12/12/2013
Dividend USD 0.4
01/13/2014
09/19/2013
Dividend USD 0.4
10/10/2013
06/20/2013
Dividend USD 0.4
07/11/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ABBV
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AbbVie Inc stock information, including NYSE:ABBV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABBV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABBV stock methods without spending real money on the virtual paper trading platform.